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Inhibition of glycine transporter-1 in the dorsal
vagal complex improves metabolic homeostasis
in diabetes and obesity
Jessica T.Y. Yue1,*,w, Mona A. Abraham1,2,*, Paige V. Bauer1,2, Mary P. LaPierre1,2, Peili Wang3, Frank A. Duca1,
Beatrice M. Filippi1, Owen Chan3 & Tony K.T. Lam1,2,4,5
Impaired glucose homeostasis and energy balance are integral to the pathophysiology of
diabetes and obesity. Here we show that administration of a glycine transporter 1 (GlyT1)
inhibitor, or molecular GlyT1 knockdown, in the dorsal vagal complex (DVC) suppresses
glucose production, increases glucose tolerance and reduces food intake and body weight
gain in healthy, obese and diabetic rats. These ﬁndings provide proof of concept that
GlyT1 inhibition in the brain improves glucose and energy homeostasis. Considering the
clinical safety and efﬁcacy of GlyT1 inhibitors in raising glycine levels in clinical trials for
schizophrenia, we propose that GlyT1 inhibitors have the potential to be repurposed as a
treatment of both obesity and diabetes.
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O
besity and diabetes have become a worldwide epidemic.
Over 2.1 billion people worldwide are overweight or
obese1 and approximately 422 million are afﬂicted with
diabetes2. Given the combined economic burden of treating both
these diseases and their complications, the development of safe
and effective therapeutic strategies is decidedly crucial.
The dysregulation of glucose and energy homeostasis in
diabetes and obesity are caused in part by the aberrant
elevation of hepatic glucose production and energy intake3,4,
pathologies which arise from the collective failure of multiple
homeostatic systems involving the liver, pancreas, adipose tissue,
brain and gastrointestinal tract4–8. As such, the development of
pharmacological approaches to restore the impaired mechanisms
within these systems is crucial to restore metabolic homeostasis in
diabetes and obesity. Neural circuits of the central nervous system
(CNS) emerge as a potential target for clinical intervention. The
recently FDA-approved anti-obesity drug, lorcaserin, activates
hypothalamic 5-HT2C receptors to reduce food intake9.
Moreover, the anti-diabetic glucagon-like-peptide 1 receptor
agonist drug, liraglutide, which is clinically demonstrated to
improve glycemia and reduce body weight10, requires activation
of neuronal glucagon-like-peptide 1 receptor to exert its anorectic
effects11. The central actions of other hormones such as insulin
further demonstrate the potential of CNS-based therapies,
as intranasal insulin delivery in humans reduces food intake12
and glucose production13 and improves whole-body insulin
sensitivity14.
CNS nutrient sensing mechanisms also reduce food intake and
body weight15 and lower glucose levels in healthy16 and diabetic17
rodents. Speciﬁcally, hypothalamic nutrient sensing activates a
forebrain–hindbrain neuronal axis involving N-methyl-D-
aspartate (NMDA) receptors in the dorsal vagal complex
(DVC) to suppress glucose production18, while these same
DVC NMDA receptors are required for intestinal sensing of
nutrients, as well as metformin and resveratrol, to lower glucose
production and food intake5,19–22. Furthermore, directly targeting
the DVC has metabolic beneﬁts, as direct administration of
glycine, an obligatory co-agonist of the NMDA receptor, into the
DVC of healthy rats lowers glucose production via NMDA
receptor activation23. Therefore, manipulating glycine levels in
the DVC could present a therapeutic target for the treatment
of obesity and diabetes. However, administration of glycine
per se is not suitable as a therapy due to its poor pharmacokinetics
in vivo.
On the other hand, regulating glycine concentration by
manipulating glycine transporters (GlyT) has demonstrated
clinical feasibility. Since glycine uptake into cells is regulated by
glycine transporters, of which GlyT1 is the primary regulator
of glycine levels in the vicinity of NMDA receptors24,
GlyT1 inhibition therefore increases extracellular glycine levels
to potentiate the activation of NMDA receptors25. Modulation of
NMDA receptor neurotransmission is currently used as a therapy
for schizophrenia, a disease that displays reduced NMDA
receptor function. In fact, the clinical trials have shown that
augmentation of NMDA receptor function via GlyT1 inhibitors
improve symptoms of schizophrenia26,27. However, no studies to
date have investigated the therapeutic potential of GlyT1
inhibition for the treatment of diabetes and obesity. Here, we
examined whether GlyT1 inhibition regulates glucose and energy
homeostasis in healthy, obese and diabetic rodents (Fig. 1a). We
demonstrate that direct inhibition of GlyT1 in the DVC confers
metabolic beneﬁts including improved glucose tolerance, lowered
glucose production, reduced feeding and lowered body weight
gain in diabetic and obese rodents. We also report that systemic
infusion of GlyT1 inhibitor recapitulates the metabolic effects of
DVC GlyT1 inhibition. Thus, inhibiting GlyT1 in the brain
represents a potential novel therapeutic strategy to lower plasma
glucose levels and body weight in diabetes and obesity.
Results
Gluco-regulation by DVC GlyT1 inhibition in healthy rodents.
To ﬁrst assess a gluco-regulatory function of GlyT1 inhibition in
physiological conditions, we infused the GlyT1 inhibitor,
ALX28,29, into the DVC of conscious, unrestrained healthy rats
and monitored plasma glucose levels during an intravenous
glucose tolerance test (ivGTT; Supplementary Fig. 1a). DVC ALX
infusion for 5 h is found to improve glucose tolerance (Fig. 1b)
independent of a rise in plasma insulin levels (Fig. 1c) compared
with DVC saline infusions. To begin delineating the mechanism
by which DVC GlyT1 inhibition improves glucose tolerance
independent of changes in insulin, we tested whether DVC GlyT1
inhibition regulates glucose production or uptake during
pancreatic basal insulin euglycaemic clamps in both rats and
mice (Supplementary Fig. 1a), since DVC glycine infusion
potentiates NMDA receptors to inhibit hepatic glucose
production23.
Infusion of ALX into the DVC of rats increases the
requirement for exogenous glucose infusion to maintain
euglycaemia (Fig. 1d) and lowers the rate of glucose production
(Fig. 1e) compared with infusions of saline, independent of
differences in glucose uptake, plasma glucose, plasma insulin or
body weight (Supplementary Fig. 1c–f). We also performed
pancreatic clamps in healthy mice that underwent stereotaxic and
vascular surgeries and demonstrated that ICV-fourth ventricle
ALX infusion correspondingly increases glucose infusion rates
and suppresses glucose production without affecting glucose
uptake or plasma glucose levels (Supplementary Fig. 2a–d).
Although inhibition of NMDA receptors with DVC infusion of
NMDA receptor blocker MK801 alone has no effect on glucose
metabolism in rats, the ability of DVC ALX infusion to increase
glucose infusion rates and suppress glucose production is
abolished with co-infusion of MK801 (Fig. 1d,e), without altering
glucose uptake or plasma glucose (Supplementary Fig. 1c,d). The
classical NMDA receptors comprised of two glycine-binding
GluN1 subunits and two glutamate-binding GluN2 subunits
require co-agonism of their subunit binding sites for activa-
tion25,30–32. Since GluN1 is an obligatory subunit31 and full
agonism at the glycine site is necessary for full NMDA receptor
activation33, we tested the gluco-regulatory ability of DVC ALX
infusion when GluN1 is inactivated. Similar to that which was
observed with NMDA receptor inhibition, speciﬁc chemical
antagonism of the GluN1 subunit of NMDA receptors with 7-
chlorokynurenic acid (7CKNA) into the DVC nulliﬁes the ALX-
induced increase of the requirement for exogenous glucose and
suppression of glucose production without affecting glucose
uptake or plasma glucose levels (Fig. 1d,e. Supplementary
Fig. 1c,d). Selective genetic inhibition of DVC GluN1 subunits
with injection of an adenoviral vector expressing GluN1 short
hairpin RNA (Ad-GluN1 shRNA) likewise reverses the ability of
ALX infusion to increase glucose infusion rates and lower glucose
production compared with adenovirus-injected mismatch
sequence (Ad-MM) controls (Fig. 1d,e, Supplementary Fig. 1c,d).
To test whether hepatic vagal innervation mediates the gluco-
regulatory effects of DVC GlyT1 inhibition, we examined the
effect of DVC ALX in rats with hepatic vagotomy versus sham
surgery. While hepatic vagotomy or sham surgery per se do not
affect glucose kinetics, the higher glucose infusion rate and lower
glucose production observed in sham rats receiving DVC ALX
compared with DVC saline are negated in hepatic vagotomized
rats, without any difference in glucose uptake or plasma glucose
(Fig. 1f,g, Supplementary Fig. 2e,f).
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We next performed microdialysis to examine the effect ALX
infused into the DVC would have on the extracellular levels of
glycine within the DVC in healthy rats in vivo (Supplementary
Fig. 1b). When ALX versus saline is infused into the DVC at a
comparable duration and dosage as the ivGTT and clamp
infusion studies in healthy rats (Supplementary Fig. 1a), ALX
versus saline results in a B2.5-fold increase in extracellular
glycine levels in the DVC (Fig. 1h). Taken together, DVC GlyT1
inhibition via ALX infusion increases glucose tolerance and
elevates extracellular glycine levels in the DVC to potentiate
NMDA receptors and activate a brain–liver axis to lower glucose
production in healthy rodents in vivo.
We alternatively tested the gluco-regulatory role of hindbrain
GlyT1 inhibition via the targeted molecular knockdown of GlyT1
within the DVC. We ﬁrst conﬁrmed that lentiviral injection of
GlyT1 shRNA (LV-GlyT1 shRNA) into the DVC selectively
reduces the expression of both the 70- and 90-kDa isoforms of
GlyT1 in plasma membrane fractions of only the DVC tissue
compared with lentiviral injection of mismatch sequence
(LV-MM), but not in the two adjacent left and right lateral
regions of the DVC containing the Spinal trigeminal track
(sp5), Spinal 5nu caudal part (Sp5C) and Spinal 5nu interpolar
(Sp5I), and the region inferior to the DVC containing
the pyramidal tract (py) of the same rats (Fig. 2a–d,
Supplementary Fig. 3i–v). The dominant band at the molecular
weight of 70–75 kDa corresponds to GlyT1a and b isoforms
and the weaker band at 90–100 kDa corresponds to GlyT1c
isoform found in the rat brain as described34. The 90–100 kDa
band is not detected in the sp5, Sp5C, Sp5I (right) and py
regions (Fig. 2c,d). The immunoblot also reveals a strong band
at 55 kDa (Fig. 2a), which is consistent with the occurrence
of the partially glycosylated form of GlyT1 in the 55–60 kDa
range as indicated35–37. However, the 55 kDa GlyT1 band in
the DVC of LV-GlyT1 shRNA versus LV-MM injected rats
is not signiﬁcantly different as compared with the effect on
70 kDa and 90 kDa bands (Fig. 2a). Nonetheless, the speciﬁc
metabolic role of various forms of GlyT1 in the brain warrants
future investigation.
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Figure 1 | Chemical inhibition of DVC GlyT1 regulates glucose homeostasis in healthy rats. (a) Schematic representation of working hypothesis:
glycine transporter-1 (GlyT1) facilitates the cellular uptake of glycine in the dorsal vagal complex (DVC). Chemical (via DVC ALX infusion) or genetic
(via DVC lentiviral injection of GlyT1 shRNA) inhibition of GlyT1 increases extracellular glycine levels in the DVC, which potentiates the activation of DVC
N-methyl-D-aspartate receptors (NMDAr) to regulate glucose production and glucose tolerance, and food intake and body weight gain. MK-801, NMDAr
ion channel blocker; 7-chlorokynurenic acid, 7CKNA-antagonist to the GluN1 subunit of NMDAr. (b) Plasma glucose levels (inset: integrated area under the
curve (AUC)) and (c) plasma insulin levels during ivGTT with DVC infusion of ALX (n¼ 8, black squares) or saline (n¼ 7, white squares). wPo0.04,
wwPo0.0008 determined by Sidak’s multiple comparisons test following repeated-measures ANOVA. *Po0.05 determined by t-test. (d) Glucose infusion
rates and (e) glucose production during clamps with DVC infusion of saline (n¼ 11), ALX (n¼9), MK801 (n¼ 9), ALXþMK801 (n¼ 5), ALXþ 7CKNA
(n¼ 5), Ad-MMþALX (n¼ 5) or Ad-GluN1 shRNAþALX (n¼ 5). (d: *Po0.002 versus saline, MK801, ALXþMK801, and ALXþ 7CKNA determined by
ANOVA and Dunnett’s post hoc test; wPo0.002 versus Ad-GluN1 shRNAþALX determined by t-test; (e) *Po0.02 versus saline, MK801, ALXþMK801
and ALXþ 7CKNA determined by ANOVA and Dunnett’s post hoc test; wPo0.0008 versus Ad-GluN1 shRNAþALX determined by t-test.) (f) Glucose
infusion rates and (g) glucose production during clamps with DVC ALX infusion in vagotomized (n¼ 7) or sham-operated (n¼ 5) rats or DVC saline
infusion in vagotomized (n¼ 7) or sham-operated rats (n¼ 5) rats. (for f and g *Po0.01 compared with all the other groups determined by ANOVA and
Dunnet’s post hoc test). (h) Extracellular glycine levels within the DVC following DVC infusion of ALX (n¼ 7) or saline (n¼ 7) in microdialysis studies.
*Po0.03 versus saline determined by t-test. Data are shown as the meanþ s.e.m.
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A 13-day chronic inhibition of GlyT1 robustly increases
glucose infusion rates (Fig. 2e) and diminishes rates of glucose
production (Fig. 2f) during the clamps, independent of changes in
glucose uptake and plasma glucose (Supplementary Fig. 4a,b).
The DVC LV-GlyT1 shRNA and -MM injected regular-chow-fed
rats received vascular surgery (for the clamp studies) on day 8
post DVC viral injection and the clamp studies were conducted
on day 13 (Supplementary Fig. 1a). The body weights of these
viral injected rats remain comparable on the morning of the
clamps at which point the rats were also fasted for 4–6 h
(Supplementary Fig. 4c). Importantly, the gluco-suppressive effect
of this chronic molecular GlyT1 inhibition is also mediated
through the activation of DVC NMDA receptors since DVC
infusion with MK801 abolishes the effect of LV-GlyT1 shRNA to
increase glucose infusion rates and lower glucose production,
unaffected by differences in glucose uptake, glycaemia or body
weight (Fig. 2e,f, Supplementary Fig. 4a–c). These molecular loss-
of-function studies strengthen the role of DVC GlyT1 inhibition
in elevating extracellular glycine levels and activating NMDA
receptors to lower glucose production in healthy rodents.
Anti-diabetic effect of DVC GlyT1 inhibition. We next sought
to ascertain a therapeutic relevance for the glucose-lowering
capacity of DVC GlyT1 inhibition ﬁrst in 3-day high-fat-diet
(3-d HFD)-fed rats (Fig. 3a). The rats placed on a 3-d HFD were
ﬁrst conﬁrmed to be hyperphagic (cumulative food intake:
258±10 versus 178±11 kcal, Po0.01 3-d HFD (n¼ 26) versus
3-d RC (n¼ 11), t-tests) and hyperinsulinemic (3-d HFD
(1.7±0.2, n¼ 5) versus 3d RC rats (0.9±0.1, n¼ 8), Po0.05,
t-tests), consistent with the fact that 3d HFD rats were validated
in parallel under hyperinsulinemic–euglycaemic clamp conditions
in our research facility to exhibit hepatic insulin resistance20. We
here evaluated whether antagonism of DVC GlyT1 modulates
glucose homeostasis in these 3-d HFD rats to the same extent as
direct DVC glycine infusion during the pancreatic (basal
insulin)–euglycaemic clamp conditions, given that DVC GlyT1
inhibition increases extracellular DVC glycine levels (Fig. 1h).
Indeed, DVC GlyT1 inhibition with ALX increases the
requirement of glucose (Fig. 3b) and suppresses the rate of
glucose production (Fig. 3c) independent of alterations in glucose
uptake (Supplementary Fig. 5a) and plasma glucose levels
(Supplementary Fig. 5b) during the pancreatic clamp in HFD
rats to the same extent as DVC glycine infusion (Fig. 3b,c).
Further, this glucose production-lowering effect of DVC ALX or
glycine in 3-d HFD rats requires the activation of the NMDA
receptor GluN1 subunits as co-infusion of 7CKNA with ALX or
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Figure 2 | Molecular inhibition of DVC GlyT1 regulates glucose homeostasis in healthy rats. (a) Representative western blots and protein levels of
plasma membrane GlyT1 (55, 70 and 90 kDa isoforms) normalized to insulin receptor (IR) in DVC wedges of rats 13-day post DVC lentiviral (LV) injection
of GlyT1 shRNA (black bars, n¼ 14) or a mismatch sequence (MM; white bars, n¼ 11) as a control. *Po0.01, **Po0.001 determined by t-test.
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sp5, Sp5C, Sp5I (R) and py wedges of rats 13-day post DVC LV injection of GlyT1 shRNA (black bars, n¼ 5) or MM (white bars, n¼ 5). (e) Glucose infusion
rates and (f) glucose production during clamps in rats injected with LV-MM (n¼ 7), LV-GlyT1 shRNA (n¼ 7) or LV-GlyT1 shRNA with DVC MK801 infusion
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glycine abates the glucose-suppressive ability of ALX and glycine
(Fig. 3b,c).
We next examined whether systemic administration of GlyT1
inhibitor ALX recapitulates the glucose production-lowering
effect of DVC ALX infused-dependent GlyT1 inhibition in 3-d
HFD-fed rats. Strikingly, constant intravenous infusion of ALX
for 5 h leads to a higher glucose infusion rate (Fig. 3d) and lower
glucose production (Fig. 3e) compared with intravenous 6%
dimethyl sulfate (DMSO) vehicle infusion during pancreatic
clamps, and these metabolic changes occur independent of
glucose uptake (Supplementary Fig. 5c) and changes in plasma
glucose levels (Supplementary Fig. 5d).
Next, we evaluated the effects of DVC ALX infusion in a rat
model of type 2 diabetes (Fig. 4a) that is considered a better
representation of humans with type 2 diabetes38. The rats were
injected with nicotinamide (Nic) and low-dose streptozotocin
(STZ) to prevent beta-cell compensation for HFD-induced
insulin resistance, and maintained on a HFD for 7 days
(Fig. 4a). We have conﬁrmed that these 7-d STZ/Nic/HFD rats
have fasting hyperglycaemia (Fig. 4b) and validated, in parallel, in
our research facility to exhibit elevated hepatic glucose
production20,21. In addition, diabetic 7-d STZ/Nic/HFDþDVC
saline-infused rats are glucose intolerant as they have markedly
elevated total glucose excursions during ivGTT compared
with their non-diabetic regular chow fed DVC saline-infused
counterparts (Fig. 4c). Interestingly, ALX infusion into the DVC
markedly lowers total glucose excursions in diabetic rats
compared with DVC saline infusion (Fig. 4c). Thus, these
experiments indicate a gluco-regulatory therapeutic potential for
DVC GlyT1 inhibition in high-fat-fed or diabetic rodents.
Metabolic beneﬁts of DVC GlyT1 inhibition in obesity. We
next assessed whether DVC GlyT1 inhibition improves glucose
metabolism in 28-d HFD-induced obese rats (Fig. 5a). The rats
fed a HFD for 28 days were ﬁrst conﬁrmed to be obese (Fig. 5b)
and hyperinsulinemic (28d HFD rats (2.5±0.2, n¼ 10) versus
28d RC rats (1.9±0.2, n¼ 9), Po0.05, t-test), consistent with the
fact that this obese model was validated in parallel under
hyperinsulinemic–euglycaemic clamp conditions in our research
facility to exhibit hepatic and peripheral insulin resistance20.
Importantly, in both 28-day regular chow and HFD cohorts, we
here report that acute inhibition of DVC GlyT1 with ALX
infusion into the DVC increases glucose infusion rates (Fig. 5c)
and lowers glucose production (Fig. 5d) independent of changes
in the glucose uptake (Supplementary Fig. 6a) and plasma glucose
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levels (Supplementary Fig. 6b) during pancreatic (basal insulin)–
euglycaemic clamp conditions. Notably, the glucose production-
lowering effect of acute DVC GlyT1 antagonism is evident in
spite of the weight gain incurred by chronic high-fat feeding
(body weight on the morning of clamp experiments: 419±7
versus 390±10 g, Po0.05 28-d HFD versus 28-d RC, t-test).
Given that acute inhibition of DVC GlyT1 improves glucose
homeostasis in short-term (Fig. 3c) and long-term high-fat-fed
rats, we postulated that chronic inhibition of GlyT1 in the
DVC might confer a gluco-regulatory beneﬁt during 28 days of
HFD-induced obesity. We tested this hypothesis by subjecting
28-d HFD-fed rats to targeted knockdown of GlyT1 in the DVC
(via DVC LV-GlyT1 shRNA injection on day 16 after HFD;
Fig. 6a) to determine whether this chronic (from day 16 to day 29;
Fig. 6a) intervention modulates glucose homeostasis. Indeed,
chronic genetic inhibition of GlyT1 in the DVC robustly increases
the glucose infusion rate (Fig. 6b) and suppresses glucose
production (Fig. 6c) as compared with MM controls. This
glucose-lowering effect occurs independent of changes in glucose
uptake (Supplementary Fig. 6c) and plasma glucose levels
(Supplementary Fig. 6d). Surprisingly, body weights on the
morning of clamp experiments are markedly lower in 28-d HFD
rats with chronic DVC GlyT1 inhibition (Fig. 6d). In fact, this
lowering of body weight in 28-d HFD-induced obese rats is
evident by day 4 post viral (LV-GlyT1 shRNA versus
LV-MM) injection (Fig. 6e). However, it is unlikely that the
gluco-regulatory improvement results from a decrease in body
weight since chronic DVC GlyT1 inhibition lowers glucose
production in healthy rats without affecting the body weight on
the morning of the clamp studies (Fig. 2f, Supplementary Fig. 4c).
DVC GlyT1 inhibition regulates energy balance. Nonetheless, it
was important to next investigate whether the local elevation of
glycine in the DVC associated with DVC GlyT1 inhibition can
also regulate energy balance. First, we tested the direct effect of
DVC glycine sensing on appetite and body weight regulation in
healthy rats that received DVC surgery 13 days prior (Fig. 7a).
Following a 22 h fast, injection of glycine into the DVC begins to
lower food intake compared with saline-infused controls by
B120min post injection and refeeding (Fig. 7a,b), an effect that
becomes signiﬁcant by 180min and persisted for 1 day after
refeeding (Fig. 7c). DVC glycine has no signiﬁcant effect on days
1 or 2 post refeeding percentage body weight gain (Fig. 7d).
Second, we assessed whether chemical inhibition of GlyT1 in the
DVC could recapitulate these glycine-induced satiation effects.
Indeed, DVC ALX injection reduces food intake by 60min after
refeeding (or 120min post-ALX injection; Fig. 7e,f) with the effect
still present 1 day post refeeding (Fig. 7g). DVC ALX also reduces
the percentage body weight gain after 1 and 2 days but not after 3
days of refeeding (Fig. 7h). Finally, we evaluated whether
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molecular inhibition of GlyT1 in the DVC could regulate energy
balance. LV-GlyT1 shRNA or LV-MM was injected into the DVC
of healthy rats to knock down DVC GlyT1, resulting in reduced
body weight of LV-GlyT1 shRNA rats 4 days post viral injection
compared with LV-MM (Fig. 7i), similar to the effect observed in
obese rats (Fig. 6e). The viral-injected regular chow-fed rats were
then subjected to a 22 h fast in the evening of day 4, and genetic
knockdown of DVC GlyT1 lowers cumulative food intake as early
as 120min following refeeding (Fig. 7j) and up to 1 day post
refeeding (Fig. 7k). In parallel, LV-GlyT1 shRNA versus LV-MM
injection lowers the percentage body weight gain following 1 and
2 days but not 3 days post refeeding (Fig. 7l).
Taken together, we provide evidence that DVC GlyT1
inhibition and subsequent glycine elevation triggers a sensing
mechanism in the DVC to lower feeding and body weight in rats.
Discussion
We have shown that targeted inhibition of DVC GlyT1 through
either administration of a GlyT1 inhibitor or a chronic molecular
knockdown improves glucose homeostasis and lowers body
weight gain in diabetic and obese rodents.
The effect of DVC GlyT1 inhibition on glucose production
regulation requires a hepatic vagal-dependent communication
between the brain and the liver. Although the neurocircuitry
involved in food intake and body weight regulation by DVC
GlytT1 inhibition (or glycine sensing) remains unclear, the
underlying neuronal relay is likely different than glucose
production regulation (since glucose production is altered by
DVC GlyT1 inhibition independent of changes in food intake
and body weight (Figs 1e, 2f and 5d), as well as blood pressure
and heart rate regulation (since DVC injection of glycine or
glutamate induce changes in blood pressure and heart rate at a
much faster rate39,40 than changes in feeding induced by DVC
glycine injection (Fig. 7b)). It would be important to follow up on
the potential long-term control of food intake and body weight
regulation via repeated injections of glycine or ALX, particularly
knowing that a knockdown of DVC GlyT1 for 13 days exerts an
anti-obesity effect.
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Although the individual cells in the DVC involved in the
metabolic control of DVC GlyT1 inhibition remain to be
identiﬁed, the potentiation and activation of the GluN1/GluN2-
containing NMDA receptor in the DVC is necessary for the
gluco-regulatory effect of DVC GlyT1 inhibition (Figs 1–3).
Given that the NMDA receptors are expressed in the plasma
membrane and are necessary for the metabolic effect of DVC
GlyT1 inhibition, DVC ALX infusion increases extracellular
glycine levels within the DVC as assessed by microdialysis
(Fig. 1h), and that DVC glycine infusion (like GlyT1 inhibition)
potentiates DVC NMDA receptors to lower glucose production in
healthy23 and 3-d HFD (Fig. 3c) rats, glycine is proposed to be the
endogenous agonist that mediate the metabolic control of DVC
GlyT1 inhibition. D-serine, like glycine, is also a co-agonist of the
NMDA receptors. However, it is unlikely that D-serine is the
endogenous agonist that mediates the effects of GlyT1 inhibition
as injection of GlyT1 inhibitor elevates extracellular glycine but
not serine and glutamate levels in the brain of rats41. Future
studies are necessary to dissect the speciﬁc role of glycine versus
serine per se as well as in the presence of GlyT1 inhibition in
regulating glucose and energy homeostasis.
Although ketamine (a partial NMDA receptor antagonist) was
used to anaesthetize the animals for brain and vascular surgeries,
any potential confounding effects of ketamine on the gluco-
regulatory studies should be absent by the time we carry out the
infusion experiments as body weight and food intake of the
rodents have fully recovered. In addition, MK-801 inhibits the
GluN1/GluN2 but not the GluN1/GluN3 NMDA receptors42.
Given that in our current study, DVC MK-801 fully reverses the
ability of both DVC ALX infusion and DVC LV-GlyT1 shRNA
viral injection to inhibit glucose production (Figs 1 and 2), it is
likely that activation of the GluN1/GluN2 receptors, and not
GluN1/GluN3, is essential for the metabolic effects of DVC GlyT1
inhibition and glycine sensing. Consistent with this hypothesis,
bi-directional changes of NMDA receptors in the DVC via DVC
infusion of NMDA or NMDA receptor antagonist AP5 alter
glucose production23, while strychnine-sensitive glycine receptors
do not appear to mediate DVC glycine sensing to regulate
glucose production23, altogether strengthening the claim that
GluN1/GluN2-containing NMDA receptors mediate the glucose-
lowering effect of DVC GlyT1 inhibition. Nonetheless, a role for
DVC GluN1/GluN3 NMDA receptor in glucose regulation
remains to be directly assessed.
DVC GlyT1 inhibition improves glucose tolerance independent
of a rise in plasma insulin levels and lowers glucose production
when insulin levels are maintained at basal during the pancreatic
clamps. Thus, it is tempting to speculate that DVC GlyT1
inhibition may improve glucose homeostasis in type 1 diabetic
insulin-deﬁcient conditions, particularly knowing that leptin
action in the brain and the gut, as well as nutrient sensing in
the gut, have been documented to improve glucose homeostasis
in insulin-deﬁcient type 1 diabetic rodents19,43–45. This working
hypothesis warrants future investigation. On the other hand, it
would also be of future interest to assess whether DVC GlyT1
inhibition reverses insulin resistance in type 2 diabetic and obese
rodents using the hyperinsulinemic–euglycaemic clamp
technique to achieve insulin-stimulated conditions.
The ﬁnding that systemic administration of ALX can recapitu-
late the glucose production-lowering effect of GlyT1 inhibition in
the DVC during the pancreatic (basal insulin)–euglycaemic clamp
setting further substantiates the potential therapeutic relevance of
GlyT1 inhibitors in diabetes and obesity. However, given that
NMDA receptors are also expressed in the islets and alter glucose-
stimulated insulin secretion46, future studies are warranted to
investigate the short- and long-term metabolic beneﬁts of ALX
administration in non-clamp conditions.
Our current set of ﬁndings serve as proof of concept for the
potential of GlyT1 inhibition as a singular therapeutic target for
the concurrent treatment of both diabetes and obesity, in addition
to its current use in the treatment of schizophrenia. Interestingly,
patients with schizophrenia have over four times the risk for
abdominal obesity and twice the risk for diabetes compared with
general population controls47, highlighting the possibility that
common pathologies may contribute to the development of these
diseases.
Among several GlyT1 inhibitors that have undergone clinical
trials, bitopertin has seen the most success by advancing to phase
III trials for the treatment of schizophrenia26,27. ALX, on the
other hand, has demonstrated relatively poorer tolerance
in vivo48. However, although ALX never entered clinical trials,
it is extensively used as a pharmacological tool for the study of
glycine transporter function48. Interestingly, DVC administration
of ALX in the present study increases DVC extracellular glycine
levels, which mimics a comparable effect of a low oral dose of
bitopertin on CSF glycine levels in rats49. These two drugs may
therefore trigger a similar degree of NMDA receptor-mediated
neurotransmissions to elicit comparable metabolic effects. Given
that several GlyT1 inhibitors have successfully demonstrated
safety and efﬁcacy in humans and that systemic ALX infusion
recapitulates the ability of ALX infusion into the DVC to lower
glucose production in HFD rats, we propose that GlyT1
inhibitors be considered as pharmacological agents for the
restoration of glucose and energy homeostasis in obesity and
diabetes.
Methods
Animal preparation and surgical procedures. Male Sprague Dawley rats
(Charles River Laboratories, Saint-Constant, QC, Canada) weighing 280–300 g
(9-week old) were used. For chronic 28-day feeding studies (see below), a separate
set of rats initially weighing 200–220 g and fed with regular chow or a high-fat diet
were used. The rats were individually housed, subjected to a standard light–dark
(7:00 light, 19:00 dark) cycle, and had ad libitum access to drinking water and
standard regular chow or a 10% lard-enriched chow (high-fat diet, HFD) where
indicated (see below). The rats were anaesthetized during surgeries (ketamine,
60mg kg 1; xylazine, 8mg kg 1). Bilateral, 26-gauge, stainless steel guide can-
nulae (Plastics One Inc, Roanoke, VA, USA) were stereotaxically implanted into
the DVC via coordinates targeting the nucleus of the solitary tract within the DVC
(NTS, 0mm on the occipital crest, 0.4mm lateral to the midline, 7.9mm below the
cranial surface; Supplementary Fig. 3)50. Eight days following DVC surgery,
indwelling catheters were surgically implanted in the left carotid artery and right
jugular vein for blood sampling and infusions, respectively51. Post-surgical body
weight and food intake were monitored daily. The rats attained a minimum of 90%
of their pre-vascular surgery body weight before undergoing experimentation 5
days following vascular surgery. The rats that did not fully recover were excluded
from the study. The rats were randomly designated into groups before experiment
and no blinding was done.
In parallel, microdialysis studies were performed on male Sprague Dawley rats
(Charles River, Raleigh, NC, USA), which started with a body weight of B280–
300 g and were individually housed in the Yale Animal Resources Center in
temperature (22–23 C) and humidity-controlled rooms. The animals had free
access to rat chow (Harlan Teklad, Indianapolis, IN, USA) and water. On arrival at
the Yale Animal Resources Center, the animals were acclimatized to handling and a
12-h light cycle (lights on between 7:00 h and 19:00 h) for 1 week before
experimental manipulation. The principles of laboratory animal care were
followed, and the experimental protocols were approved by the Institutional
Animal Care & Use Committee at the Yale University. The rats were anaesthetized
with isoﬂurane and the heads were positioned into a stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA). A single stainless steel guide cannula for
microinjection and microdialysis (Eicom Corporation, Japan) was implanted
intracranially using the following stereotaxic co-ordinates from Paxinos and
Watson (0mm on the occipital crest, 5mm medial–lateral and 7.4mm ventral at an
angle of 35 for microdialysis). This targeted the 1mm microdialysis probe (Eicom
Corporation, Japan) to the NTS within the DVC.
The male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME, USA) at
18 weeks of age were housed in a standard light–dark cycle with ad libitium access
to drinking water and standard chow. The mice were anaesthetized during
stereotaxic and vascular surgeries (Avertin, 0.6mg g 1). A unilateral, 33-gauge,
stainless steel guide cannula (Plastics One Inc) was stereotaxically implanted into
the fourth ventricle (ICV-4; 6.0mm posterior to Bregma, 4.0mm below the cranial
surface)52,53. One week following ICV-4 surgery, an indwelling catheter was
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surgically implanted in the right jugular vein52,53. Post-surgical body weight and
food intake were monitored daily. The mice attained a minimum of 90% of their
pre-vascular surgery body weight before undergoing pancreatic clamp 3–5 days
following vascular surgery.
All the experimental animal procedures in this study were reviewed and
approved by the Institutional Animal Care and Use Committee of the UHN.
Intravenous glucose tolerance test. The experiments were performed in
overnight-fasted (16 to 18 h) male Sprague Dawley rats 5 days after vascular
catheterization. The basal blood samples were obtained in conscious, unrestrained
rats immediately before the start of DVC infusions (0.33 ml h 1, CMA 400 syringe
pump, CMA Microdialysis, Inc., North Chelmsford, MA, USA) of 0.9% saline
or ALX (ALX 5407, Tocris Bioscience, 40 nM), which were commenced at
t¼ 240min and maintained until the end of the experiment at t¼ 60min
to ensure that rats received the same duration of DVC treatment as clamp
experiments (see below). After t¼ 0min, the blood samples were obtained,
an intravenous bolus of glucose (20% glucose, 0.25 g kg 1) was injected and
ﬂushed with saline. The injections were administered via the jugular vein catheter,
and the blood was sampled from the carotid artery catheter to measure plasma
glucose and insulin levels for 60min following glucose injection as described53.
Pancreatic basal insulin euglycaemic clamp in rats. The experiments
were performed in male Sprague Dawley rats fasted for B4–6 h before clamp
experiments to ensure comparable post-absorptive nutritional status. The basal
blood samples were obtained in conscious, unrestrained rats immediately before
the start of DVC infusions (0.33 ml h 1) of the following infusates: (i) 0.9% saline,
(ii) MK801 (0.06 ngmin 1, dissolved in saline), (iii) 7CKNA (7-chlorokynurenic
acid, 30 mM, dissolved in saline), (iii) ALX (ALX 5407, Tocris Bioscience, 40 nM,
dissolved in saline), (iv) ALX (40 nM)þMK801 (0.06 ngmin 1), (v) ALX
(40 nM)þ 7CKNA (30 mM), (vi) glycine (10 mM, dissolved in saline). Using the
same DVC infusion protocol as the current study, glycine at 10 mM was validated to
elevate DVC glycine levels by B1.2-fold and lower glucose production23 and
secretion of triglyceride-rich very-low-density lipoproteins (VLDL-TG)50 in regular
chow-fed healthy rats, while MK-801 at 0.06 ngmin 1 and 30mM of 7CKNA
blocked the effects of DVC glycine infusion to lower glucose production23 and
VLDL-TG secretion50. Thus, we have chosen to use these same dose and
concentrations for the inhibitors in this study examining the effect of DVC GlyT1
inhibition (likely mediating glycine sensing). In fact, a total amount of B20 ng of
MK-801 was delivered into the DVC over the course of 330min in the current
studies, which is comparable to the 50 ng of MK-801 delivered into the NTS
(or DVC) that regulated feeding behaviour54. Similarly, our concentration of
30mM 7CKNA was also well within the range reported by the other studies that
have indicated that 10–50 mM of 7CKNA reduces 80–90% of glycine binding to rat
cerebral cortex synaptic plasma membrane55, while 30mM of 7CKNA inhibits
NMDA-induced transmitter release from rat hippocampal slices56. More
importantly, DVC infusion of neither MK-801 at 0.06 ngmin 1 nor 30mM
7CKNA per se resulted in increased glucose production but only blocked the effect
of DVC glycine infusion to lower glucose production23. Thus, any concern for the
non-speciﬁc effects of these inhibitors in regulating glucose homeostasis can be
safely excluded. The concentration of 40 nM ALX was chosen based on the IC50 of
ALX for GlyT1 (4 nM; ref. 29) and factoring into a dilution factor when chemical
inhibitors are infused into the DVC. Infusions of MK801 or 7CKNA, when used, or
saline as a control, were commenced at t¼  90min; infusions of ALX±MK801
or 7CKNA were commenced at t¼  60min and infusions of glycine±7CKNA
were commenced at t¼ 0min and maintained for the duration of the experiment.
ALX, an inhibitor of the GlyT1 transporter, inhibits the binding of glycine to its
cellular transporter and elevates extracellular levels of glycine41. ALX infusion was
initiated earlier to allow for extracellular levels of glycine in the DVC to
accumulate. Clamp methodology was performed as follows53. A primed,
continuous infusion (PHD2000 syringe pump, Harvard Apparatus, Saint Laurent,
QC, Canada) of [3-3H]-glucose (PerkinElmer; 40 mCi bolusþ 0.4 mCi infusion) was
commenced at t¼ 0min and maintained until the end of the clamp experiment at
t¼ 240min to measure glucose kinetics using tracer-dilution methodology. The
glucose turnover was calculated using steady-state formulae, in which the rate of
appearance of glucose is calculated using [3-3H]-glucose. The total rate of
appearance of endogenous glucose production is equivalent to the rate of glucose
utilization during the basal period (t¼ 60–90min). The pancreatic basal insulin–
euglycaemic clamp was initiated at t¼ 90min with the primed continuous infusion
of insulin (1.2mU kg 1min 1, somatostatin (SST, 3 mg kg 1min 1) and a
variable infusion of 25% glucose to maintain glycemia at a similar level to the basal
period and was maintained until t¼ 240min. Plasma samples were obtained every
10min for the determination of [3-3H]-glucose speciﬁc activity and glucose levels.
Wedges containing the DVC, the left and right portions of spinal trigeminal tr.
(sp5), Spinal 5nu caudal part (Sp5C), Spinal 5nu, interpolar (Sp5I) and the
pyramidal tr. (py) (Supplementary Fig. 3i–v, see ‘Brain tissue sampling’ section
below) were collected immediately after the experiments, frozen in liquid nitrogen
and stored at  80 C for analysis.
Hepatic branch vagotomy in rats. A separate set of male Sprague Dawley rats
underwent hepatic branch vagotomy23 on the same day as vascular catheterization
surgeries. The hepatic branch of the ventral subdiaphragmatic vagal trunk was
transected, and the omentum between the liver and the esophagus was severed such
that any tissue connections between the liver and the esophagus were removed. The
neural communication between the central nervous system and the liver was
disrupted upon transection of the hepatic vagal nerve, and to a much lesser degree,
the innervations to the gut were also disrupted. The sham-operated rats underwent
similar procedure except for transection of the vagus. After surgical recovery, the
rats underwent clamp experiments as described above.
Microdialysis. One week after surgery, the male Sprague Dawley rats were fasted
for 4–6 h before the experiments to ensure comparable post-absorptive nutritional
status. On the day of the study, the microdialysis-microinjection probe was inserted
through the guide cannula and the animals were allowed to recover for 2.5 h before
collection of the baseline sample (Supplementary Fig. 1b). Artiﬁcial extracellular
ﬂuid was perfused through the probe at a rate of 0.5 ml min 1 throughout the
study. Following the recovery period, we collected a baseline sample over the
course of 2 h before the start of ALX (40 nM in saline, Tocris Bioscience) infusion.
The ALX was infused into the DVC (via the microinjection needle) at a rate of
0.33 ml h 1 for a total duration of 300min. The microdialysate samples were
collected at 60, 180 and 300min following the start of ALX infusion. The control
animals were infused with saline and sampled under similar conditions. At the end
of the study, the animals were killed with an overdose of sodium pentobarbital.
DVC virus injection. Immediately after stereotaxic surgery while anaesthetized,
3 ml of adenovirus or lentivirus were injected over 30 s in each of the DVC cannulae
with microsyringes. An adenovirus expressing shRNA to the GluN1 subunit of the
NMDA receptor (Ad- GluN1 shRNA, 4.0 1011 p.f.u. ml 1) or a mismatch
sequence as a control (Ad-MM, 4.0 1011 p.f.u. ml 1) was injected into the DVC
for one set of experiments using the same protocol that we have validated23. This
adenoviral GluN1 shRNA knockdown procedure decreases GluN1 protein levels
speciﬁcally in the DVC region23. In separate sets of experiments, a lentivirus
expressing shRNA to GlyT1 (LV-GlyT1 shRNA, 1.0 106 infectious units;
sc-270432-V, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or a mismatch
sequence as a control (LV-MM, 1.0 106 infectious units; sc-108080, Santa Cruz
Biotechnology) was injected in the DVC. Eight days after DVC cannulation and
virus injection, vascular catheterization was performed as described above in rats
that would undergo clamp experiments. Thirteen days after DVC cannulation,
virus-injected rats underwent clamp or feeding experiments as described above.
Brain tissue sampling in rats. At the end of the experiments, the rats were
injected with 3 ml bromophenol blue through each side of the bilateral DVC
catheter to verify the correct placement of the catheter for the viral injection
studies, while bromophenol blue was co-infused with chemical reagents for
the non-viral injection studies. Once the whole brain is harvested from the
anaesthetized rat via decapitation, the cerbellum is lifted to expose the caudal part
of the brain (Supplementary Fig. 3i–v). Only those data for rats that showed
injection of dye within the vagal triangle (Supplementary Fig. 3ii–v) were
included. A spatula was used to extract the section of vagal triangle overlaying
the DVC (blue; Supplementary Fig. 3ii–v). In addition, sections of tissues were
dissected out from the left (yellow) and right (purple) lateral regions of the caudal
brain containing sp5 (spinal trigeminal tr.), Sp5C (spinal 5nu, caudal part), Sp5I
(spinal 5nu, interpolar), as well from the lower region containing py (pyramidal tr)
of the distal caudal brain (green; Supplementary Fig. 3ii–v).
Microdialysate sample glycine analysis. Microdialysate samples collected at
baseline, 180 and 300min were analysed using a ﬂuorometric assay kit (Glycine
assay kit (Fluorometric), #K589-100, Biovision Incorporated, Milpitas, CA, USA)
according to the manufacturer’s directions. A sample volume of 50 ml was used in
the assay and since glycine content was low, each microdialysate sample was spiked
with 0.3 nmol of the glycine standard to bring the values within a more reliable
reading range of the assay and the calculations were adjusted accordingly. Since
glycine levels were relatively stable during ALX infusion, the concentrations
obtained from the last two microdialysate samples were averaged together and
compared with the baseline levels. Similar calculations were performed for the
control animals.
Acute (3-day) and chronic (28-day) high-fat feeding in rats. Two separate
sets of male Sprague Dawley rats were fed a palatable, 10% lard-enriched HFD
(TestDiet #571 R, Purina Mills, Richmond, IN, USA), either for 3 days (acute,
3-d HFD) or 28 days (chronic, 28-d HFD) before the clamp experiments. The
composition of the HFD (3.9 kcal g 1) differs from regular chow (3.1 kcal g 1):
fat content (34% versus 18%); protein (22% versus 33%) and carbohydrate
(44% versus 49%) content. A 28-day regular chow-fed cohort of rats was used
in parallel to the 28-d HFD group. Both cohorts of HFD rats underwent the
pancreatic clamp experiments as described above. The rats that did not overeat
were excluded from the studies.
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Intravenous ALX infusion clamps. In a separate group of 3-d HFD-fed male
Sprague Dawley rats, the pancreatic clamp experiments were performed as
described above, with the exception that a continuous intravenous ALX
(4.1mg kg 1min 1, dissolved in 6% DMSO infused at 20 ml min 1) or
intravenous 6% DMSO (20 ml min 1) as vehicle was initiated at t¼  90min.
At t¼ 0min, a primed continuous infusion of 3[H3]- glucose was commenced
and maintained until the end of the experiment, t¼ 210min. At t¼ 90min, the
pancreatic basal insulin clamp was initiated with the primed continuous infusion
of insulin (1.2mU kg 1min 1), somatostatin (SST, 3 mg kg 1min 1), and a
variable infusion of 25% glucose to achieve euglycaemia was administered until
t¼ 210min. Intravenous ALX was constantly infused at 4.1 mg kg 1min 1 to
achieve a total amount of 1.23mg kg 1 ALX delivered into the blood in 300min.
This choice of dose is based on the fact that intravenous ALX injected at
1-2mg kg 1 has been documented to potentiate NMDA-evoked ﬁring in PFC
neurons of rats in vivo57.
Induction of experimental type 2 diabetes. Six days after DVC surgery,
a separate set of male Sprague Dawley rats was given an intraperitoneal injection of
nicotinamide (Nic, 170mg kg 1) followed by an intraperitoneal low-dose injection
of streptozotocin (STZ, 65mg kg 1) 15min later and fed with a HFD for 7 days as
described20,21,38, before intravenous glucose tolerance tests as described above. The
rats that did not present with fed hyperglycaemia (for example, 49mM) were
excluded from the study.
Fasting–refeeding experiments. Separate groups of male Sprague Dawley rats
were subjected to a 22-h fast (food removed at 7 pm) before undergoing the
refeeding experiment. DVC injections (0.04 ml min 1 for 5min using CMA syringe
pumps) of 0.9% saline, ALX (40 nM) or glycine (10 mM) were given at t¼  60min
(ALX) or t¼  10min (glycine; Fig. 7a,e). To prevent backﬂow of the injected
volume, injection cannulae were left in guide cannulae for an additional 5min with
the pump off, and dummy cannulae are re-inserted and secured with dust caps.
Regular chow was returned to cages at 17:00 h, t¼ 0min. The food intake was
measured every 30min for the ﬁrst 4 h of the refeeding experiment, and every 1 h
until t¼ 360min. Food intake and body weight were measured again 20 h (day 1)
and 44 h (day 2) after the rats were refed.
Pancreatic basal insulin euglycaemic clamp in mice. The experiments were
performed in male C57BL/6 mice fasted for B4–6 h before clamp experiments to
ensure comparable post-absorptive nutritional status. The basal blood samples
were obtained in conscious, unrestrained mice immediately before the start of
ICV-4 infusions (1.02ml h 1) of saline or ALX (40 nM), which were commenced at
t¼  90min and maintained for the duration of the experiment. The clamp
methodology in mice was performed as follows53. A primed, continuous infusion
of [3-3H]-glucose (1 mCi bolusþ 0.1 mCi infusion) was commenced at t¼ 0min
and maintained until the end of the clamp experiment at t¼ 180min to measure
glucose kinetics. The basal period was deﬁned as t¼ 50–60min. The pancreatic
basal insulin-euglycaemic clamp was initiated at t¼ 60min with a primed
continuous infusion of insulin (1.4mU kg 1min 1, SST (8.3mg kg 1min 1),
and a variable infusion of 10% glucose to maintain glycaemia at a similar level to
the basal period and was maintained until t¼ 180min. The plasma samples were
obtained every 10min for the determination of [3-3H]-glucose speciﬁc activity and
glucose levels.
Western blot analyses. GlyT1 protein levels were measured in puriﬁed plasma
membrane fractions of brain tissue wedges from the rats that received LV GlyT1
shRNA or LV MM injections. The brain tissue wedges were collected 13 days
following lentivirus injection and immediately frozen in liquid nitrogen and stored
at  80 C until analysis. Puriﬁed plasma membrane protein fractions were iso-
lated using a commercial kit suitable for mammalian tissues (Plasma Membrane
Protein Extraction Kit #K268-50, BioVision Incorporated, Milpitas, CA, USA)51.
Puriﬁed plasma membrane fraction protein concentrations were measured using a
BCA Protein Assay kit (#K812-1000, BioVision Incorporated) and 6 mg of protein
was subjected to electrophoresis on 8% polyacrylamide gels and transferred to
nitrocellulose membranes. The membranes were incubated with blocking solution
(5% BSA in Tris-buffered saline containing 0.2% Tween-20 (TBS-T)) for 1 h at
room temperature and overnight at 4 C in primary antibody solutions diluted
1/1,000 in 5% BSA in TBS-T of GlyT1 (ab113823 rabbit, Abcam, Cambridge, MA,
USA), or insulin receptor (IR) b (L55B10 mouse, #3020, Cell Signaling Technology,
Danvers, MA, USA) after 10min shaking in antibody stripping buffer (Gene
Bio-Application Ltd, Yavne, Israel) and re-blocked as above. Protein expression
was detected using an HRP-linked secondary antibody (rabbit and mouse,
respectively, diluted 1/4,000 in blocking solution) and an enhanced
chemoluminescence reagent (Pierce ECL Western Blotting Substrate, Thermo
Scientiﬁc, Rockford, IL, USA). Immunoblots were detected using a MicroChemi 4.2
chemiluminescent imaging system and quantiﬁed with GelQuant image analysis
software (DNR Bio-Imaging Systems, Jerusalem, Israel). Plasma membrane GlyT1
protein levels were normalized to the plasma membrane protein levels of IR. See
Supplementary Fig. 7 for uncropped blots.
Biochemical analysis. Plasma glucose concentrations were measured by the
glucose oxidase method (Glucose Analyzer GM9, Analox Instruments, Lunenburg,
MA, USA). Plasma insulin levels were determined by radioimmunoassay (Millipore
Canada Ltd, Etobicoke, ON, Canada).
Calculations and statistics. The sample size for each group was chosen on the
basis of study feasibility and prior knowledge of statistical power form previously
published experiments. For pancreatic clamp experiments in rats, measurements
during t¼ 60–90min were averaged for the basal period, and t¼ 210–240min, and
where possible t¼ 180–210min were averaged for the clamp period. In mice,
measurements during t¼ 50–60min were averaged for the basal period and
t¼ 160–180min were averaged for the clamp period. Integration of the area under
the curve was calculated with GraphPad Prism 6 software (LaJolla, CA, USA).
Unpaired Student’s t-tests were performed in the statistical analysis of two groups.
Where comparisons were made across more than two groups, analysis of variance
(ANOVA) was performed, and if signiﬁcant, was followed by Dunnett’s or Tukey’s
post hoc tests when appropriate. The measurements that were taken repeatedly over
time were compared using repeated-measures ANOVA; if the time and treatment
interaction between groups was found to be signiﬁcant, Sidak’s multiple compar-
isons test or t-tests were used to determine the statistical signiﬁcance at speciﬁc
time points between groups. Differences in the overall effects of HFD diet on body
weight are indicated where signiﬁcance was found following repeated-measures
ANOVA. The P value o0.05 was considered statistically signiﬁcant.
Data availability. All the relevant data are available from the authors on request
and/or are included within the manuscript (and its Supplementary Information
ﬁles).
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